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Urinary proteomic biomarkers in coronary artery disease
Abstract
Urinary proteomics is emerging as a powerful non-invasive tool for diagnosis and monitoring of variety
of human diseases. We tested whether signatures of urinary polypeptides can contribute to the existing
biomarkers for coronary artery disease (CAD). We examined a total of 359 urine samples from 88
patients with severe CAD and 282 controls. Spot urine was analyzed using capillary electrophoresis
on-line coupled to ESI-TOF-MS enabling characterization of more than 1000 polypeptides per sample.
In a first step a "training set" for biomarker definition was created. Multiple biomarker patterns clearly
distinguished healthy controls from CAD patients, and we extracted 15 peptides that define a
characteristic CAD signature panel. In a second step, the ability of the CAD-specific panel to predict the
presence of CAD was evaluated in a blinded study using a "test set." The signature panel showed
sensitivity of 98% (95% confidence interval, 88.7-99.6) and 83% specificity (95% confidence interval,
51.6-97.4). Furthermore the peptide pattern significantly changed toward the healthy signature
correlating with the level of physical activity after therapeutic intervention. Our results show that
urinary proteomics can identify CAD patients with high confidence and might also play a role in
monitoring the effects of therapeutic interventions. The workflow is amenable to clinical routine testing
suggesting that non-invasive proteomics analysis can become a valuable addition to other biomarkers
used in cardiovascular risk assessment.
Page 1 of 34 
Urinary proteomic biomarkers in coronary artery disease 
 
LU Zimmerli1*§, E Schiffer2*, P Zürbig2, DM Good3, M Kellmann4, L Mouls5, AR Pitt5, JJ Coon3, 
RE Schmieder6, KH Peter7, H Mischak2, W Kolch5,8, C Delles1, AF Dominiczak1# 
 
1BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK 
2Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany 
3Departments of Chemistry and Biomolecular Chemistry, University of Wisconsin-Madison, 
Madison, USA 
4Thermo Fisher Scientific, Bremen, Germany 
5Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, UK 
6Department of Medicine IV, Nephrology and Hypertension, University of Erlangen-Nürnberg, 
Germany 
7Baker Heart Research Institute, Melbourne, Australia 
8The Beatson Institute for Cancer Research, Glasgow, UK 
 
* Contributed equally 
 
Running title: Biomarkers for coronary artery disease 
 
# Corresponding author 
AF Dominiczak, BHF Glasgow Cardiovascular Research Centre, 126 University Place, 
University of Glasgow, Glasgow G12 8TA, United Kingdom. phone: +44 141 330 5420, fax: 
+44 141 330 6997, email: ad7e@clinmed.gla.ac.uk 
 
§ Current address of LUZ: Medical Outpatient Department, University Hospital, CH- 4031 
Basel, Switzerland 
 MCP Papers in Press. Published on October 19, 2007 as Manuscript M700394-MCP200
 Copyright 2007 by The American Society for Biochemistry and Molecular Biology, Inc.
 at SM
AC Consortium
 - University of Zürich on February 5, 2010 
w
w
w
.m
cponline.org
D
ow
nloaded from
 
Page 2 of 34 
ABBREVIATIONS 
CAD   Coronary artery disease 
CE-ESI-TOF-MS Capillary electrophoresis online coupled to electrospray ionization –  
   time of flight mass spectrometry 
CRP   C-reactive protein 
MDRD   Modification of Diet in Renal Disease 
ETD   Electron transfer dissociation 
MS   Mass spectrometry 
ROC   Receiver Operating Characteristics Curve 
AUC   Area under the ROC curve 
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SUMMARY 
Urinary proteomics is emerging as a powerful non-invasive tool for diagnosis and monitoring 
of variety of human diseases. We tested whether signatures of urinary polypeptides can 
contribute to the existing biomarkers for coronary artery disease (CAD). We examined a total 
of 359 urine samples from 88 patients with severe CAD and 282 controls. Spot urine was 
analyzed using capillary electrophoresis online coupled to electrospray ionization- time of 
flight mass spectrometry (CE-ESI-TOF-MS) enabling characterization of more than 1000 
polypeptides per sample. In a first step a “training set” for biomarker definition was created. 
Multiple biomarker patterns clearly distinguished healthy controls from CAD patients and we 
extracted 15 peptides that define a characteristic CAD signature panel. In a second step, the 
ability of the CAD specific panel to predict presence of CAD was evaluated in a blinded study 
using a “test set”. The signature panel showed sensitivity of 98% [95% CI 88.7 to 99.6] and 
83% specificity [95% CI 51.6 to 97.4]. Further, the peptide pattern significantly changed 
towards the healthy signature correlating with the level of physical activity after therapeutic 
intervention. Our results show that urinary proteomics can identify CAD patients with high 
confidence, and might also play a role in monitoring the effects of therapeutic interventions. 
The workflow is amenable to clinical routine testing suggesting that non-invasive proteomic 
analysis can become a valuable addition to other biomarkers used in cardiovascular risk 
assessment. 
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INTRODUCTION 
Coronary artery disease (CAD) is a leading cause of morbidity and mortality world-wide. The 
underlying molecular causes are still largely unknown, but are likely to involve alterations in 
gene and protein expression (1). Despite multiple clinical, electrographic and biochemical 
characteristics, there are subgroups of patients who progress to severe, life threatening CAD 
without much symptoms and signs (2). For example, patients with type 2 diabetes and the 
elderly frequently suffer from silent myocardial infarctions with significantly increased risk of 
complications (3). Early diagnosis of CAD in its presymptomatic stage would allow for better, 
targeted and hence more effective primary prevention as compared to current clinical 
recommendations. Proteomics is increasingly used to examine dynamic changes in protein 
expression providing new insights into cellular processes. Moreover, proteomic analyses 
have already resulted in the identification of clinically useful biomarkers and can assist in 
diagnosis and disease staging (1, 4, 5). Substances contained in body fluids hold an 
abundance of information, and can be used as a dynamic and concurrent gauge for 
monitoring the wellbeing of an organism. Urine presents a rich source of information related 
to the functioning of many internal organs (5-7) and the appearance of certain proteins in the 
blood stream may result in their appearance in the urine either in the intact form or as 
peptide fragments. The protein and peptide composition of the urine is determined by the 
function of the glomerular filtration apparatus, proximal tubular absorption of ultrafiltered 
proteins and the capacity of the brush-border and lysosomal proteolytic machinery to 
degrade filtered proteins (8). Therefore, detection of one or several proteins or polypeptides 
may provide a signature of a particular pathological process (7). 
We hypothesized that proteomic analysis of urine should yield a panel of biomarker peptides 
useful as additional tools for the diagnosis and monitoring of CAD. Further, we aimed to 
obtain sequences of biomarkers of the CAD signature panel in order to gain insight into 
pathogenetic mechanisms and facilitate comparison with currently used biochemical 
markers. Capillary electrophoresis online coupled to electrospray ionization- time of flight 
mass spectrometry (CE-ESI-TOF MS) seems ideally suited for this purpose due to its non-
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invasive nature, high resolution and amenability for future adaptation to clinical laboratory 
analysis (5).  
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EXPERIMENTAL PROCEDURES 
Subjects and procedures 
We enrolled 88 patients with CAD confirmed by coronary angiography. Patients were 
recruited at the Western Infirmary, Glasgow. Eighty two of the 88 patients were re-assessed 
after a further 14 weeks, one patient died and five patients refused to participate at a follow-
up examination. At both assessments blood and midstream spot-urine samples were 
collected. Thirty two subjects with no history of angina, CAD, or peripheral artery disease, 
who were recruited from a local health club and from surgical wards at Gartnavel General 
Hospital, Glasgow, served as controls. Plasma total cholesterol, low-density lipoproteins, 
high-density lipoproteins, triglycerides, high sensitivity CRP and serum creatinine were 
assessed using standard biochemical methods. The MDRD formula was used for the 
estimation of glomerular filtration rate in study participants (9). 
Vascular stiffness was assessed by two methods. First, pulse contour analysis of the 
diastolic pressure decay was used to estimate large (C1) and small artery compliance (C2, 
HDI/Pulse Wave CR2000, HDI Inc., Eagan MN, USA) based on a three-element Windkessel 
model (10). Second, augmentation index of the central aorta was derived from the radial 
pulse waveform using a generalized transfer function (SphygmoCor pulse wave analysis 
system, AtCor Medical, West Ryde, NSW, Australia) (11). The augmentation index was 
calculated from the ratio of the pulse pressure at the second systolic peak to that at the first 
systolic peak.  
The study was approved by the West Glasgow Ethics Committee and all subjects gave 
written informed consent. The design of this study is according to current guidelines for 
studies on clinical proteomics (12) and the minimum information about proteomics 
experiments (MIAPE) (13). 
To exclude the effect of medication, 17 paired urine samples from age and sex-matched 
patients with hypertension and type 2 diabetes, but without albuminuria, before and 12 
weeks after commencing treatment with the angiotensin-converting enzyme inhibitor ramipril 
(5 to 10 mg o.d.) were evaluated. To rule out centre specific bias, samples from 233 new 
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appointees at the University of Hannover who were free of self-reported illness were also 
analyzed. 
Detailed characteristics of all patients and controls are shown in Table 1 with additional data 
on 233 healthy University recruits and 18 ramipril patients shown in Table 2. 
Physical activity levels in CAD patients 
At follow-up examination, self-reported physical activity was assessed. The physical activity 
was graded into two categories: no regular physical activity (patients mainly confined 
indoors) or low-grade physical activities like walking on flat terrain or non-strenuous 
gardening and a very active group with hiking, biking and golfing several times a week. This 
classification was independently validated by physiotherapists who categorized patients’ 
activity levels according to clinical data (r=0.379, P=0.006). Furthermore, physiotherapists 
performed an incremental shuttle walk test (14) after baseline examination in 52 of the 88 
patients. There was a significant correlation between metabolic equivalent obtained by the 
test and self-reported activity (r=0.399, P=0.003).  
Urine sample preparation and CE-MS analysis 
After collection, all the spot-urine samples were frozen at -80 °C until analysis. For proteomic 
analysis samples were prepared as previously described (15, 16). CE-MS analysis was 
performed as described (15-17) using a P/ACE MDQ capillary electrophoresis system 
(Beckman Coulter, Fullerton, CA, USA) on-line coupled to a Micro-TOF MS (Bruker Daltonic, 
Bremen, Germany). The performance of the sample preparation procedure as well as the 
analytical performance of the instrumental setup was evaluated (5, 18). The average 
recovery of the sample preparation procedure is approximately 85% with a detection limit of 
~1 fmol. The monoisotopic mass signals could be resolved for z≤6. The mass accuracy of 
the CE-TOF-MS method was determined to be <25 ppm for monoisotopic resolution and 
<100 ppm for unresolved peaks (z>6). The precision of the analytical method was 
determined by assessing (a) the reproducibility achieved for repeated measurement of the 
same aliquot and (b) by the reproducibility achieved for repeated preparation and 
measurement of the same urine sample (5, 18). The 200 most abundant polypeptides were 
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detected with a rate of 98%. The performance of the analytical system over time was 
assessed with consecutive measurements of the same aliquot over a period of 24 h. No 
significant loss of polypeptides was observed implying the stability of the CE-MS set up, the 
post preparative stability of the urine samples at 4  C and their resistance to e.g. oxidizing 
processes or precipitation (5, 18). 
Data processing and cluster analysis 
Data processing and cluster analysis were performed as previously described (15, 19). Only 
signals observed in a minimum of 3 consecutive spectra with a minimum signal-to-noise ratio 
of 4 were considered. Mass spectral ion peaks representing identical molecules at different 
charge states were deconvoluted into single masses using either the distance between 
resolved isotope peaks of the ion or according to conjugated signals for unresolved isotope 
peaks [MosaiquesVisu software (16, 18)]. In addition, migration time and ion signal intensity 
(amplitude) were normalized using internal polypeptide standards (15). The resulting peak 
list characterizes each polypeptide by its molecular mass [kDa], normalized migration time 
[min], and normalized signal intensity. All detected polypeptides were deposited, matched, 
and annotated in a Microsoft SQL database, allowing further analysis and comparison of 
multiple samples (patient groups). Polypeptides within different samples were considered 
identical if the mass deviation was less than 100 ppm and the migration time deviation was 
less than 3 %. CE-MS data of all individual samples can be accessed in the Supplementary 
Tables. 
Definition of biomarkers and sample classification 
For biomarker panel definition, we used polypeptides that were found in more than 75% of 
the urine samples in at least one of the different groups of the training set (e.g. CAD or 
healthy controls). Polypeptides fulfilling this criterion were further evaluated using ROC 
statistics (20). The amplitude distribution of the CE-MS data of polypeptides present in the 
samples was used as the ROC variable and the affiliation to a diagnostic group (i.e. CAD or 
healthy control) as the classification variable. The obtained AUC value of the analysis of a 
given polypeptide was interpreted as a measure of its discriminatory potential. An initial list of 
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potential marker candidates was further refined using Mann-Whitney test with P≤0.05 as 
significance level. Model establishment and sample classification was performed by using a 
linear classifier algorithm according to i
i
i AcF log∑=  with F as classification factor, ci as 
classification coefficient, and Ai as amplitude of the CE-MS signal of the marker i. The 
algorithm generates a classification model based on polypeptides that are best suited to 
discriminate between two defined sample groups. Models consist of less biomarkers than 
samples to avoid over-fitting of models. The probability to have CAD at a given classification 
factor F taking into account the related probability for a negative diagnosis was calculated 
according to 
X
PCAD +
=
1
1
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Pattern composition 
For the first phase of the study a training set was established. The training set consisted of 
50 urine samples from randomly selected subjects, 30 CAD patients and 20 control subjects, 
respectively. The first step of biomarker selection led to a set of 187 potential CAD specific 
polypeptides.  
In a second step, these pre-selected polypeptides were compared with 233 urine samples 
from healthy volunteers from different centers to eliminate polypeptides that may show centre 
specific bias. To exclude the effect of medication on constituting markers, an additional 
control group of patients before (n=15) and after (n=17) 12-week treatment with the 
angiotensin-converting enzyme ramipril was used to refine the selected polypeptides. 
Polypeptides that showed up/down regulation of CE-MS signal intensity in direct comparison 
of both groups and in addition a uniform behavior in pair wise comparison in the majority of 
patients, were considered as medication artifacts and eliminated.  
Subsequently, the established pattern of 15 polypeptides was evaluated in a blinded 
assessment of 59 urine samples; 47 from patients with CAD and twelve samples from 
healthy controls. All samples were examined employing the CAD panel. Seventy six urine 
samples from follow-up examination were also evaluated employing the CAD panel.  
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Sequencing of polypeptides 
Peptide sequencing was performed using an LTQ Orbitrap hybrid mass spectrometer 
(Thermo Fisher Scientific, Bremen, Germany) equipped with a Dionex Ultimate 3000 
nanoflow system and a nano-electrospray ion source. Peptide separation took place on a 
5 µm C18 nanocolumn (NanoSeparations, Nieuwkoop, Netherlands) in a pre-column setup 
using a flow rate of 5 µL/min followed by a flow of 250 nl/min and a linear gradient (60min) 
from 2–50% MeCN in H2O (0.1% formic acid). The mass spectrometer was operated in data-
dependent mode to automatically switch between MS and MS/MS acquisition. Survey full 
scan MS spectra (from m/z 300–2000) were acquired in the Orbitrap with resolution 
R=60,000 at m/z 400 (target value of 500,000 charges in the linear ion trap). The most 
intense ions were sequentially isolated for fragmentation in the linear ion trap using 
collisionally induced dissociation and the detection took place either in the linear ion trap 
(parallel mode; target value 10,000) or in the Orbitrap (target value of 500,000). Orbitrap 
MS/MS were acquired with resolution R=15,000 at m/z 400. General mass spectrometric 
conditions were: electrospray voltage, 1.6 kV; no sheath and auxiliary gas flow; ion transfer 
tube temperature, 225 °C; collision gas pressure, 1 .3 mT; normalized collision energy, 32% 
for MS/MS. Ion selection threshold was 500 counts for MS/MS. 
Further analysis was performed using instruments with electron transfer dissociation (ETD) 
capability (21-23). Upon arrival, samples were resuspended (50µL 100mM Acetic Acid), 
bomb-loaded onto a 360 x 75µm microcapillary pre-column, and connected to a 360 x 50µm 
analytical column with a ~ 1µm tip pulled with a laser puller (both columns were packed in-
house with ~5-8 cm of C18 resin). Peptides were separated by nRP-HPLC (Agilent 1100; 
flow split by tee to ~100nL/min) and introduced into either an ETD-enabled LTQ quadrupole 
linear ion trap (Thermo Fisher Scientific, San Jose, CA) or LTQ-Orbitrap (Thermo Fisher 
Scientific, Bremen, Germany) mass spectrometer, also capable of ETD analysis, via nano-
ESI. Samples analyzed using the LTQ were run in a data-dependent manner, with the 5 most 
abundant species subjected to both ETD and CAD fragmentation (in separate alternating 
scans). Ion trap instrumental parameters were employed as described recently (24). LTQ-
 at SM
AC Consortium
 - University of Zürich on February 5, 2010 
w
w
w
.m
cponline.org
D
ow
nloaded from
 
Page 11 of 34 
Orbitrap analyses were performed using SMART ETD and SMART MSN, according to 
parameters previously presented (25). Targeted analyses were also performed with the LTQ-
Orbitrap, where target m/z’s of interest, which were observed in CE-MS analyses but were 
not previously characterized, were inspected. Spectral data was converted into .dta files 
(DTA’s) using Bioworks Browser and MakeDTA (a gift from Don Hunt) for CAD and ETD, 
respectively. CAD and ETD DTA’s were subsequently made into separate batches of ~2,000 
files each. Alternatively, LC-MALDI-TOF and LC-QTOF peptide sequencing was performed 
as described in detail elsewhere (26). 
Identification of peptide sequences. 
MS/MS data were submitted to MASCOT (www.matrixscience.com) for a search against 
human entries in the MDSB Protein Database. Accepted parent ion mass deviation was 50 
ppm; accepted fragment ion mass deviation was 500 ppm. All search results with a MASCOT 
peptide score better than 20, depending on the ion coverage as related to the main spectra 
features, were accepted. Data files were also searched against the NCBI human non-
redundant database using the Open Mass Spectrometry Search Algorithm (OMSSA), with an 
e-value cut-off of 0.01. The number of basic and neutral polar amino acids of obtained 
peptide sequences was utilized to correlate peptide sequencing data to CE-MS data as 
described earlier (26).  
Statistical Analyses 
All of the statistical analyses for patient characteristics and clinical data were performed 
using Minitab (Minitab for Windows 12.21, Minitab Inc., State College PA, US) software 
package. The Kolmogorov-Smirnov test was used to test for normal distribution of the data. 
Data are expressed as mean ± standard deviation if normally distributed or median 
(interquartile range) if their distribution was not normal. Categorical variables are presented 
as frequency counts, and intergroup comparisons were analyzed by χ2-test for smoking, sex 
and medication with statins. For continuous variables, differences between the groups were 
evaluated using unpaired Student’s t-test or Mann-Whitney U-test for variables that were 
normally distributed and those not normally distributed, respectively.  
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Estimates of sensitivity and specificity were calculated based on tabulating the number of 
correctly classified samples. Confidence intervals (95% CI) were calculated in MedCalc 
(MedCalc for Windows 8.1.1.0, Medcalc Software, Mariakerke, Belgium). The Receiver 
Operating Characteristic (ROC) plot was obtained by plotting all sensitivity values (true 
positive fraction) on the y axis against their equivalent (1-specificity) values (false positive 
fraction) for all available thresholds on the x axis (MedCalc Software). The area under the 
ROC curve (AUC) was evaluated as it provides a single measure of overall accuracy that is 
not dependent upon a particular threshold (20). 
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RESULTS 
Details of patients and controls are given in Table 1. Control subjects had lower blood 
pressure and CRP levels compared to CAD patients. Due to treatment with statins total 
cholesterol and LDL cholesterol levels were lower in patients with CAD than in healthy 
controls. However, control subjects had higher HDL cholesterol levels and were more likely 
to be never smokers compared to patients with CAD. Renal function was similar in both 
groups. Compared to control subjects the augmentation index was higher, and large and 
small artery elasticity indices were lower in patients with CAD. 
At baseline evaluation, mid-stream urine specimens were available from 86 out of 88 
patients; nine out of 86 urine samples did not fulfill quality control criteria (15). Of the 
remaining 77 samples, 30 have been used to establish a training set, and 47 were evaluated 
in a blinded assessment (Table 2). The 77 patients who entered analysis did not differ in 
clinical characteristics from the 88 originally included in the study. In addition to healthy 
controls from the same population (Glasgow, UK), a group of healthy controls from another 
population (Hannover, Germany) and patients before and after treatment with ramipril 
(Nürnberg, Germany) were used to rule out centre-specific bias and effect of medication on 
constituting markers, respectively (Table 2). At follow-up evaluation only 5 of the 82 urine 
samples failed quality control criteria. 
Samples were analyzed by CE-MS and biomarker peptide patterns distinguishing CAD from 
healthy controls could be established (Figure 1 and Table 3). The discriminatory ability of 
the classification factor F to distinguish CAD and healthy controls in the training set was 
assessed using ROC analysis and showed an AUC of 0.96 (Figure 2A). A classification 
threshold FCAD=13.0 classified the training set with sensitivity of 97% [95% CI 83 to 99] and 
specificity of 80% [95% CI 56 to 94]. Furthermore, a test set including patients after coronary 
artery bypass graft surgery and patients after acute coronary syndrome was subject to a 
blinded study. Out of 59 urine samples 48 scored positive as “CAD”, and 11 scored negative 
as healthy controls using the threshold of FCAD=13.0. After unblinding, 46/47 CAD samples 
and 10/12 healthy control samples were predicted correctly (Figure 2C) with sensitivity of 
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98% [95% CI 89-99] and specificity of 83% [95% CI 52 to 97]. A ROC analysis showed an 
AUC of 0.94 (Figure 2B).  
 
We used a fixed classification factor threshold (FCAD=13.0) to calculate sensitivity and 
specificity, and were able to generate a risk profile for patients having CAD. This is 
demonstrated by the significant differences between F values obtained in patients with CAD 
vs. healthy controls. Mean F value for all CAD samples (n=47) was 16.55 ± 2.0 while that for 
control samples (n=12) was 9.04 ± 4.8 (P<0.001) (Figure 2C). The calculated F value and 
the resulting F value for each patient’s urine sample can be used to predict the risk for CAD. 
The probability of CAD at a given classification factor F taking into account the related 
probability for no disease was calculated and PCAD was plotted against the obtained F values 
(Figure 2D). 
 
To test whether this assessment can also be used to evaluate the effects of therapeutic 
interventions, we analyzed patients who had undertaken different levels of physical exercise. 
Self-reported and physiotherapist-validated activity levels determined improvement of the 
classification factor between baseline and follow-up assessment. At follow-up assessment 
the classification factor was almost unchanged in inactive and low-grade active patients (∆F= 
-0.20), while the very active patient group (∆F= -1.90) showed a significant improvement 
(P=0.02). 
 
In order to determine the identity of biomarkers in the panel (Table 3) used to distinguish 
CAD from healthy controls we performed liquid chromatography tandem mass spectrometry 
(LC-MS/MS) to obtain sequence information. Examples of sequences deduced from high-
resolution fragmentation spectra are shown in Figure 3 and five sequences of biomarkers in 
the panel could be identified: Collagen α-1(I) chains and Collagen α-1(III) fragments (Table 
4). In all cases, the identified collagen type I or III fragments were up-regulated in CAD 
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samples compared to controls. From the initial marker list 38 polypeptides (supplementary 
table) could be identified. The majority of these sequences were collagen fragments.  
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DISCUSSION 
The aim of our study was to establish and validate a proteome-based non-invasive method 
for the detection and follow up of CAD. Therefore, we tested whether CE-MS can resolve 
signature patterns of urinary polypeptides (15), that can be used as biomarkers .  
 
Our polypeptide pattern distinguished between presence and absence of disease. 
Furthermore, we were also able to demonstrate a dynamic behavior of the polypeptide 
pattern in response to exercise. Inactive patients had no change in pattern over time, while 
very active patients showed significant changes towards a “healthier” biomarker pattern. 
These results illustrate an important difference between proteomic versus genomic analysis. 
Genomic analysis identifies predisposing risk factors, while proteomics can identify the point 
in time when predisposition is developing into disease. This is because the proteome is 
inherently dynamic and hence can better reflect changes (27). This also pertains to 
measuring the effects of therapeutic interventions and will assist in personalized medicine 
strategies. Furthermore, this observation would also provide a link between the kidney and 
CAD on a molecular basis, and may help to explain why chronic kidney disease is one of the 
best predictors for CAD (28). 
For a reliable CAD specific polypeptide panel it is mandatory that the constituting markers 
are independent of medication effects as the majority of patients require multiple drugs 
including anti-hypertensives. As an example, we used an additional control group of patients 
before and after treatment with angiotensin converting enzyme inhibitor, ramipril, to refine 
selected polypeptides. This comparison offered a more precise and sensitive monitoring of 
medication effect independent of individual fluctuations in urinary peptide patterns. The 
obtained polypeptide pattern was validated using a test set including patients with CAD in 
addition to healthy controls.  
 
We were also able to identify five of the polypeptides constituting the CAD specific panel: all 
of them were collagen type I or III fragments. These collagens are predominant proteins in 
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the arterial walls. They also appear together in the thickened intima of atherosclerotic lesions 
(29). Collagen is synthesized containing C-terminal and N-terminal propeptide sequences 
(PICP and PINP for type I procollagen; PIIICP and PIIINP for type III procollagen). These 
propeptides are used as biomarkers of the rate of collagen synthesis (PICP), collagen 
degradation (ICTP) and collagen turnover (PIIINP) (30-34). In the normal artery, both 
synthesis and degradation of extracellular matrix proteins are remarkably slow. 
Atherosclerosis leads to increased synthesis of many matrix components, including collagen 
types I and III, elastin and several proteoglycans (35). 
All sequenced collagen fragments were up-regulated in CAD samples compared to controls. 
In line with these sequence data suggesting elevated collagen degradation levels, increased 
circulating levels of collagenases, such as MMP-9, have been reported in patients with stable 
angiographic coronary atherosclerosis (36, 37) or intermittent claudication (38). In patients 
with stable CAD, circulating MMP-9 levels independently predict rapid lumen diameter 
reduction (39) and fatal cardiovascular events (40). Elevated MMP-9 activity has been found 
in unstable plaques, suggesting a crucial role in plaque rupture (41, 42).  
The majority of the identified polypeptides constituting the initial marker list were also 
collagen fragments (Supplementary Table). These findings suggest that CAD-specific 
information is redundantly available in urine samples in the form of different detectable 
collagen fragments. In addition to the collagen fragments, a fragment of membrane-
associated progesterone receptor component 1 was identified (Supplementary Table). 
Progesterone receptors are reported to be found associated with thoracic ascending aorta, 
internal carotid, coronary artery, and left atrial appendage (43). 
 
Several groups have reported on the application of proteomics techniques to analyze tissue 
or plaque specimens to study cardiovascular disease or arteriosclerosis (44-48). Although 
these results provide new insights into disease related pathways, they do not allow non-
invasive detection of coronary artery disease. Only a few of these studies focused on the 
analysis of body fluids derived through minimally invasive means. Furthermore, these studies 
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were either based on pooled blood specimens (49, 50), making individual sample 
classification impossible, or they included only small patient cohorts without blinded studies 
for validation (51). All of these limitations are avoided in our study. The proteomic analysis of 
urine allowed for the reproducible and standardized analysis of a non-invasively obtained 
body fluid for highly accurate detection of CAD, which was subsequently validated in a 
blinded study. 
 
In summary, in this patient population a CAD specific urinary proteome panel is an accurate 
and non-invasive predictor for CAD. These and other similar biomarkers have the potential to 
be used for early diagnosis and thus more efficient prophylaxis as well as monitoring of 
therapeutic interventions and as novel drug targets.  
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FIGURE LEGENDS 
 
Figure 1: Polypeptide patterns distinguishing patients with coronary artery disease (CAD) 
from controls. This figure shows the compiled data sets of 30 CAD samples (upper left panel) 
and 20 control subjects (upper right panel) of the training set (Table 2). Normalized 
molecular weight is plotted against normalized migration time. The mean signal intensity is 
given in 3D-depiction. The lower panel depicts the 15 indicative polypeptides defining the 
specific pattern for CAD (lower left panel) and controls (lower right panel). 
 
Figure 2: A: ROC curve of the proteomics panel diagnosis: Using the CAD specific 
polypeptide panel from Table 3 the classification factor F is used as variable in ROC analysis 
in the 50 samples of the training set (CAD and Controls in Table 2, bold line, AUC=0.97) and 
B: in the 59 samples of the test set (CAD and Controls in Table 2, bold line, AUC=0.94). 
95 % confidence intervals (95% CI) are indicated by thin lines. C: Box-and-whisker plots of 
classification factor F obtained for classification of the test set (Table 2). The boxes depict 
the quartiles Q1 and Q3 of each distribution; the statistical medians are shown as horizontal 
lines in the boxes. The whiskers indicate 3/2 times the interquartile range of Q1 and Q3. D: 
CAD probabilities of the 59 urine samples of the test set are plotted against the classification 
factor F=Σci log Ai. 
 
Figure 3. A: High-resolution MS/MS spectrum (lower Panel) of 1435.72 Da polypeptide 
indicative for CAD (Table 3). It was found to be up regulated in CAD samples compared to 
control samples (Table 1). SwissProt database matching indicated this is a fragment of 
Collagen α-1 (I) chain [543-558] [H. sapiens] with a calculated mass of 1435.72 Da and a 
sequence as indicated (upper Panel). B: MS/MS spectrum (lower Panel) of 1834.90 Da 
polypeptide (Table 3) up regulated in CAD samples (Table 1). Database matching indicated 
this is a fragment of Collagen α-1 (III) chain [642-661] [H. sapiens] with a calculated mass of 
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1834.83 Da and a sequence as indicated (upper Panel). The masses of b-ion fragments and 
y-ion fragments are correlated with the obtained sequence using fragment numbers (52, 53). 
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Table 1: Demographics and Clinical Data 
 
 
Controls 
n=32 
CAD, baseline 
n=77 
CAD, follow-up 
n=82 
P 
Sex, male/female 21/9 56/21 59/23 0.91 
Age, y 54±13 61±11 † 62±11 N/A 
BMI, kg/m2 25.3±3.1 26.2±4.8 26.5±4.6 0.38 
Smokers, active/stopped/none 3/9/20 14/38/25 * 13/42/27 0.93 
Diabetic, n 0 6 7 0.84 
Statin therapy, n 0 75‡ 77 0.93 
Systolic blood pressure, mmHg 123±12 132±20 † 133±19 0.42 
Diastolic blood pressure, mmHg 76±7 76±9 74±9 0.15 
Total cholesterol, mmol/L 5.4±0.9 3.9±0.8 ‡ 3.8±0.8 0.24 
LDL cholesterol, mmol/L 3.2±0.7 1.9±0.7 ‡ 1.8±0.8 0.13 
HDL cholesterol, mmol/L 1.5±0.4 1.2±0.3 † 1.3±0.3 0.12 
Triglycerides, mmol/L 1.3 (1.0;2.7) 1.5 (1.8;2.2)  1.4 (1.1;2.1) 0.48 
C-reactive protein, mg/L 1.3 (0.3;2.4) 2.6 (1.0;6.3) † 1.2 (0.6;2.2) <0.001 
Creatinine, µmmol/L 90±9 91±21 98±23 0.03 
eGFR, mL/min/1.73m2 75±10 75±9 69±14 <0.001 
AI, % 26.4±11.7 32.1±10.4 * 30.5±9.4 0.18 
C1, mL/mmHg*10 14.0±3.9 11.8±4.3 † 13.3±4.3 0.01 
C2, mL/mmHg*100 5.7±3.9 3.8±2.8 † 3.6±1.6 0.50 
 
CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; AI, Augmentation Index; C1, Large Artery Elasticity Index; C2, Small 
Artery Elasticity Index. P values are given for the comparison between CAD at baseline and CAD at follow-up. Significant differences between 
Controls and CAD at baseline are indicated by symbols (* P<0.05, † P<0.01, ‡ P<0.001). 
 at SMAC Consortium - University of Zürich on February 5, 2010 www.mcponline.org Downloaded from 
 28 
Table 2: Characteristics of the training and the test set  
 
 Training Set Test Set 
 CAD * Controls * Ramipril 
Samples 
Hannover 
Samples 
CAD * Controls * 
Total number of patients 30 20 18 232 47 12 
Sex, male/female 22/8 14/6 14/4 101/137 34/13 7/5 
Age 62±11 54±13 59±11 34±11 61±12 54±12 
BMI, kg/m2 25.9±3.8 25.7±3.5 30.5±5.0  26.5±5.3 24.8±2.2 
Smoker, yes/no 5/25 2/18 4/14  8/39 1/11 
Diabetic, n 1 0 18  5 0 
Systolic blood pressure, mmHg 133±19 123±11 151±13  132±20 124±13 
Diastolic blood pressure, mmHg 75±11 76±7 86±10  76±8 75±8 
Total cholesterol, mmol/L 3.9±0.8 5.2±1.0 5.5±1.3  3.9±0.9 5.6±0.6 
LDL cholesterol, mmol/L 1.9±0.6 3.0±0.8 3.4±1.0  1.9±0.8 3.4±0.6 
HDL cholesterol, mmol/L 1.2±0.3 1.4±0.4 1.3±0.3  1.2±0.3 1.6±0.4 
Triglycerides, mmol/L 1.6 (1.2;2.4) 1.3 (1.1;2.5) 1.6 (1.0;2.7)  1.4 (1.2;1.9) 1.3 (1.0;1.6) 
 
CAD, coronary artery disease 
* In all depicted parameters there were no differences between CAD patients and controls in the training set and test set, respectively.  
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Table 3: CAD polypeptide panel 
 
Polypeptide Identification CAD HC P-Value 
Protein-
ID 
Mass 
[Da] 
Migration 
time 
[min] 
Median IQR Median IQR 
 
629 838.44 35.05 0.0 74.6 151.4 259.2 0.0003 
948 858.43 23.26 20.0 95.8 112.2 156.9 0.0469 
994 860.40 26.23 0.0 39347.0 149.0 269.8 0.0006 
16954 1435.72 28.86 6167.6 3515.3 2896.3 2872.6 0.0111 
18225 1487.71 29.58 344.6 560.9 803.6 673.8 0.0459 
21244 1623.8 24.15 7087.0 4054.0 4074.9 3193.8 0.0017 
22223 1664.82 29.87 891.3 359.5 443.0 658.5 0.0019 
25791 1834.9 31.15 5309.2 9423.3 1205.1 924.4 0.0018 
27916 1933.95 21.63 785.7 677.4 207.2 341.3 0.0026 
30362 2056.02 25.44 1047.1 687.7 555.9 444.9 0.0005 
31262 2104.04 33.04 2985.6 1463.6 1951.9 1117.4 0.0174 
32138 2150.04 27.76 2344.2 1112.7 1429.7 1277.5 0.0023 
52939 3137.51 30.32 602.6 547.1 154.9 303.8 0.0001 
53283 3158.60 26.69 767.8 1133.9 182.0 753.8 0.0052 
81912 5574.44 23.22 238.4 489.3 568.9 346.6 0.0442 
 
*Polypeptide markers derived from training set of 30 CAD patients and 20 healthy controls 
(Online Table 1). 
 
ID, polypeptide ID annotated by the SQL database as described in the methods section; 
Mass, molecular weight [Da]; Migration time, normalized to an array of 200 polypeptides 
frequently found in urine. 
 at SM
AC Consortium
 - University of Zürich on February 5, 2010 
w
w
w
.m
cponline.org
D
ow
nloaded from
 
 30 
Table 4: Sequence data*  
 
Polypeptide Identification Sequence information 
Protein-
ID* 
Experiment
al Mass 
[Da] 
Migration 
time 
[min] 
Sequence Name 
Calculat
ed Mass 
[Da] 
Mass 
Deviation 
[ppm] 
16954 1435.72 28.86 SPhGSPGPDGKTGPPhGP 
Collagen α-1(I) 
chain [543-558] 
[H.sapiens] 
1435.66 43 
21244 1623.80 24.15 DGAPhGKNGERGGPhGGPhGP 
Collagen α-1(III) 
chain [587-604] 
[H.sapiens] 
1623.72 41 
25791 1834.90 31.15 GLPhGTGGPPhGENGKPhGEPGPh 
Collagen α-1(III) 
chain [642-661] 
[H.sapiens] 
1834.83 34 
27916 1933.95 21.63 GDDGEAGKPGRPhGERGPPhGP 
Collagen α-1(I) 
chain [230-249] 
[H.sapiens] 
1933.89 34 
53283 3158.60 29.69 
GERGSPhGGPhGA
AGFPhGARGLPhGP
hPGSNGNPGPPhG
Ph 
Collagen α-1(III) 
chain [861-895] 
[H.sapiens] 
3158.44 51 
 
*Sequence data obtained from polypeptides in Table 3 
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SUPPLEMENTARY TABLE LEGENDS 
 
Table consists of 9 different spreadsheets called (1) CAD_specific_panel (2) training_set, (3) 
quality_control, (4) test_set, (5) polypeptides, (6, 7, 8) patients_raw data_part 1 to 3, and (9) 
Biomarker list. 
 
(1) CAD_specific_panel. Table lists classification factors ci (manuscript Methods) and 
protein_IDs of the polypeptides constituting the CAD specific panel.  
(2): training_set. Table illustrates the classification factors F obtained for each of the 50 
patient samples of the training set (manuscript Table 2) using the CAD specific panel 
(Table 3). Column 1 gives a unique sample identifier (sample_ID), column 2 the obtained 
classification factor Fi. Column 3 depicts the clinical diagnosis, 1 means CAD diagnosed, 0 
not. 
(3): Quality_control. Table assigns sample_ID (column 1) to the patient group (column 2). 
(4): Test_set. Table comparable to (2). Samples of patients with CAD are marked with *. 
(5): Polypeptides. Table listing all 5855 different polypeptides (protein_ID) detected, their 
calibrated molecular mass (Da), and normalized CE migration time. 
(6, 7, 8): Patients_raw data_part 1 to 3. Tables in pivot format show the CE-MS data of the 
409 samples used in the study. Only data that were actually utilized (that are present in at 
least 40% of the samples of one of the diagnostic groups, see Materials and Methods) are 
shown. The protein IDs of all polypeptides are given in the first column named “protein_ID”, 
the unique sample_IDs constitute the first row. The MS data from each sample are reflected 
in one column. The number in each cell represents the calibrated amplitude of the mass 
spectrometric signal of each polypeptide detected in the sample. The table is divided into 
four spreadsheets, since Microsoft Excel limits the maximal number of columns to 256.  
(9): Initial biomarker list in CAD patients including sequence information of identified 
polypeptides. 
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